Canopus BioPharma Incorporated
Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and chan… Read more
Canopus BioPharma Incorporated (CBIA) - Total Liabilities
Latest total liabilities as of May 2023: $191.11K USD
Based on the latest financial reports, Canopus BioPharma Incorporated (CBIA) has total liabilities worth $191.11K USD as of May 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Canopus BioPharma Incorporated - Total Liabilities Trend (2013–2022)
This chart illustrates how Canopus BioPharma Incorporated's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Canopus BioPharma Incorporated Competitors by Total Liabilities
The table below lists competitors of Canopus BioPharma Incorporated ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Avix Technologies Inc
PINK:AVIX
|
USA | $160.90K |
|
SFLMaven Corp
PINK:SFLM
|
USA | $102.02K |
|
Medican Enterprises
PINK:MDCN
|
USA | $19.82 Million |
|
Snoogoo Corp
PINK:SGOO
|
USA | $725.89K |
|
Nexity Financial Corporation
PINK:NXTYQ
|
USA | $1.00 Billion |
|
Greyson International Inc
PINK:GYSN
|
USA | $872.08K |
|
Newron Sport
PINK:NSPT
|
USA | $185.29K |
Liability Composition Analysis (2013–2022)
This chart breaks down Canopus BioPharma Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 31.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Canopus BioPharma Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Canopus BioPharma Incorporated (2013–2022)
The table below shows the annual total liabilities of Canopus BioPharma Incorporated from 2013 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-08-31 | $17.50K | -99.17% |
| 2014-08-31 | $2.11 Million | -52.02% |
| 2013-08-31 | $4.39 Million | -- |